All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Impact of allo-HSCT on survival outcomes in accelerated/blast-phase MPN
|
A multicenter analysis that evaluated the survival outcomes associated with first-line treatment, response, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with accelerated/blast-phase myeloproliferative neoplasms (MPN-AP/BP) has been published in Blood Advances by Patel et al.1 |
| Key learnings1 |
|
Across 9 academic centers, the three most common first-line treatments for adult patients with MPN-AP/BP were intensive chemotherapy (IC), DNA methyltransferase inhibitor (DNMTi)-based regimens, and DNMTi combined with venetoclax (VEN). |
|
The median overall survival (OS) for patients with MPN-AP/BP was 0.86 years, regardless of first-line treatment. |
|
The median OS for patients who underwent allo-HSCT was 2.3 years from the time of transplant. |
|
These data highlight an unmet need in treating MPN-AP/BP, suggesting that current therapies provide limited survival benefits in the absence of allo-HSCT. |
|
There is a need for further research and development of more effective treatments for patients who are ineligible for or unable to receive allo-HSCT. |
- Patel A, Yoon J, Johnston H, et al. Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era. Blood Adv. 2024. Online ahead of print. DOI: 10.1182/bloodadvances.2024012880
More about...
Your opinion matters
21 votes - 19 days left ...
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox